Acorda Pharmaceuticals Seeks $66M as Federal Circuit Hears Multiple Sclerosis Drug Patent Appeal

In a recent patent battle, Acorda Pharmaceuticals appealed to the Federal Circuit, urging them to award the company an additional $66 million over the already secured $16.5 million it won in an arbitration case against Alkermes, a Dublin-based biopharmaceutical company. The dispute lays its foundation in a licensing disagreement revolving around a drug intended for multiple sclerosis treatment, with Acorda alleging the tribunal blatantly overlooked established patent law.More details on this case can be found on Law360.